Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy

Journal of B.U.ON.

Volumn 14, Issue 3, 2009, Pages 463-472

  Zissimopoulos, Athanasios ^a   Stellos, K ^b   Matthaios, D ^a   Petrakis, G ^c   Parmenopoulou, V ^a   Babatsikou, F ^d   Matthaiou, E ^c   Theodosiadou, E ^a   Hountis, P ^e   Koutis, C ^d  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d UNIVERSITY OF WEST ATTICA   (Greece)

^e MOUNT SINAI HOSPITAL   (United States)

Author keywords

Bone metastases; Cancer; ICTP; PICP

Indexed keywords

ANTINEOPLASTIC AGENT; CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1 TELOPEPTIDE; PRO TYPE 1 COLLAGEN PEPTIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLADDER CANCER; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HORMONAL THERAPY; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATE HYPERTROPHY; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; COLLAGEN TYPE I; FEMALE; HUMANS; IMMUNORADIOMETRIC ASSAY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCIN-1; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 70350050229     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kozlow W, Guise TA. Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia 2005; 10: 169-180. (Pubitemid 41031006)
2. Zissimopoulos A, Matthaios D, Matthaiou E, Mantadakis E, Karaitianos I. Association between bone scintigraphy and serum levels of tumor markers in the detection of bone disease in breast cancer patients. J BUON 2007; 12: 505-511.
3. Stoll BA. Natural history, prognosis and staging of bone metastases. In: Stoll BA, Parbho S. (Eds): Bone metastases monitoring and treatment. New York, Raven Press, 1983.
4. Tamura M, Oda M, Tsunezuka Y et al. Chest CT and serum vascular endothelial growth factor-C level to diagnose lymph node metastasis in patients with primary non-small cell lung cancer. Chest 2004; 126: 342-346. (Pubitemid 39093414)
5. Rubins JB, Dunitz J, Rubins HB et al. Serum carcinoembryonic antigen as an adjunct to preoperative staging of lung cancer. J Thorac Cardiovasc Surg 1998; 116: 412-416. (Pubitemid 28400171)
6. Ferrigno D, Buccheri G. Clinical applications of serum markers for lung cancer. Respir Med 1995; 89: 587-597.
7. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350: 2129-2139. (Pubitemid 38637993)
8. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006; 355: 570-580. (Pubitemid 44200650)
9. Grossman HB, Messing E, Soloway M et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005; 293: 810-816. (Pubitemid 40250364)
10. Hemstreet GP 3rd, Yin S, Ma Z et al. Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine. J Natl Cancer Inst 2001; 93: 427-436.
11. Smith SD, Wheeler MA, Plescia J et al. Urine detection of survivin and diagnosis of bladder cancer. JAMA 2001; 285:324-328. (Pubitemid 32095036)
12. Konety BR, Getzenberg RH. Urine based markers of urological malignancy. J Urol 2001; 165: 600-611.
13. Gazdar AF, Czerniak B. Filling the void: Urinary markers for bladder cancer risk and diagnosis. J Natl Cancer Inst 2001; 93: 413-415. (Pubitemid 32266526)
14. Cassel A, Rahat MA, Lahat N et al. Telomerase activity and cytokeratin 20 as markers for the detection and follow-up of transitional cell carcinoma: an unfulfilled promise. J Urol 2001; 166: 841-844. (Pubitemid 32750960)
15. Raitanen MP, Kaasinen E, Rintala E et al. Prognostic utility of human complement factor H related protein test (the BTA stat Test). Br J Cancer 2001; 85: 552-556. (Pubitemid 32808280)
16. Van Rhijn BW, Lurkin I, Kirkels WJ et al. Microsatellite analysis-DNA test in urine competes with cystoscopy in follow-up of superficial bladder carcinoma: a phase II trial. Cancer 2001; 92: 768-775. (Pubitemid 32783061)
17. Sarosdy MF, Kahn PR, Ziffer MD et al. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria. J Urol 2006; 176: 44-47. (Pubitemid 43833178)
18. Pirtskalaishvili G, Getzenberg RH, Konety BR. Use of urine-based markers for detection and monitoring of bladder cancer. Tech Urol 1999; 5: 179-184.
19. Lokeshwar VB, Soloway MS. Current bladder tumor tests: does their projected utility fulfil clinical necessity? J Urol 2001; 165: 1067-1077.
20. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridoniline cross-linked carboxy-terminal telopeptide of type 1 collagen: an new serum marker of bone collagen degradation. Clin Chem 1993; 39: 635-640. (Pubitemid 23118314)
21. Campbell PC, Blarney RW, Woolfson AM, Elston CW, Hosking DJ. Calcium excretion (CaE) in metastatic breast cancer. Br J Surg 1983; 70: 202-204.
22. Francini G, Gonnelli S, Petrioli R et al. Procollagen type I carboxy-terminal propeptide as a marker of osteoblastic bone metastases. Cancer Epidemiol Biomarkers Prev 1993; 2: 125-129.
23. Melkko J, Niemi S, Risteli L, Risteli J.Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36: 1328-1332. (Pubitemid 20251932)
24. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71: 1061-1064.
25. Igawa T, Sakai H, Kanetake H, Saito Y. Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer. Hinyokika Kiyo 1999; 45: 235-239.
26. Savolainen ER, Goldberg B, Leo MA, Valez M, Lieber CS. Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease. Alcohol Clin Exp Res 1984; 8: 384-389. (Pubitemid 14064969)
27. Chybowski FM, Kellr JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-318.
28. Westerhuis LW, Delaere KP. Diagnostic value of some biochemical bone markers for the detection of bone metastases in prostate cancer Eur J Clin Chem Clin Biochem 1997; 35: 89-94.
29. Perachino M, Di Ciolo L, Barbetti V, Puppo P. Procollagen type I carboxyterminal extension peptide in serum: a reliable marker of bone metastatic disease in newly diagnosed prostate cancer? Eur Urol 1996; 29: 366-369.
30. Hosoya Y, Arai K, Honda M, Sumi S, Yoshida K. Serum levels of the carboxy-terminal propeptide of type I procollagen and the pyridinoline cross-linked carboxy-terminal telopeptide of type 1 collagen as markers of bone metastases in patients with prostate carcinoma. Eur Urol 1997; 31: 220-223. (Pubitemid 27101712)
31. Nakashima J, Sumitomo M, Miyajima A et al. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer. J Urol 1997; 157: 1736-1739. (Pubitemid 27171764)
32. Kylmala T, Tammela TL, Risteli L, Risteli J, Kontturi M, Elomaa I. Type I collagen degradation product (ICTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br J Cancer 1995; 71: 1061-1064.
33. Jukkola A, Tahtela R, Tholix E, et al. Aggressive breast cancer leads to discrepant serum levels of the type I procollagen propeptides PINP and PICP. Cancer Res 1997; 57: 5517-5520. (Pubitemid 28006758)
34. Shimozuma K, Sonoo H, Fukunaga M, Ichihara K, Aoyama T, Tanaka K. Biochemical markers of bone turnover in breast cancer patients with bone metastases: a preliminary report. Jpn J Clin Oncol 1999; 29: 16-22.
35. Blomqvist C, Risteli L, Risteli J, Virkkunen P, Sarna S, Elomaa I. Markers of type I collagen degradation and synthesis in the monitoring of treatment response in bone metastases from breast carcinoma. Br J Cancer 1996; 73: 1074-1079. (Pubitemid 26131227)
36. Ebert W, Muley T, Herb KP, Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients Anticancer Res 2004; 24: 3193-3201.
37. Ylisirnio S, Sassi ML, Risteli J, Turpeenniemi-Hujanen T, Jukkola A. Serum type I collagen degradation markers, ICTP and CrossLaps, are factors for poor survival in lung cancer. Anticancer Res 1999; 19: 5577-5581. (Pubitemid 30093331)
38. Aruga A, Koizumi M, Hotta R, Takahashi S, Ogata E. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer 1997; 76: 760-764. (Pubitemid 27379743)
39. Lorenzo G. The role of tumor markers in urologic consultation for screening, diagnosis, and follow-up of bladder cancer. Actas Urol Esp 2003; 27: 110-116.
40. Li F, Iqbal J, Wassif W, Kaddam I, Moniz C. Carboxyterminal propeptide of type I procollagen in osteomalacia. Calcif Tissue Int 1994; 55: 90-93.